Sign Up to like & get
recommendations!
2
Published in 2023 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izad012
Abstract: Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.
read more here.
Keywords:
therapy associated;
delays therapy;
inflammatory bowel;
current prior ... See more keywords